- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
The Top 5 Biosimilars Articles for the Week of February 26
The Center for Biosimilars recaps the top 5 biosimilars articles for the week of February 26, 2018.
Transcript:
Hi, I’m Kelly Davio for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of February 26.
Number 5: The US Patent Trial and Appeal Board has decided that the Saint Regis Mohawk Tribe cannot claim sovereign immunity from inter partes review of Allergan’s patents covering Restasis, and that the proceedings can continue with Allergan as the patent owner.
Number 4: Infliximab has been proposed as a potential combination treatment that could enhance the effects of chemotherapy in patients with colon cancer.
Number 3: The American College of Rheumatology has updated its health policy statements for 2018, and biosimilars featured heavily in the organization’s concerns for the year ahead.
Number 2: Virginia’s House and Senate have passed a new bill that prohibits pharmacy benefit managers from penalizing pharmacists for sharing drug price information with customers.
Number 1: A health economist from Harvard Medical School is warning that, if biosimilars continue their current trajectory, they could fail to deliver on their promise to provide cost savings to the US health system.
Finally, last week, our e-newsletter asked for your thoughts on whether the extrapolation of indications for biosimilars is reasonable.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Review Calls for Path to Global Harmonization of Biosimilar Development Regulations
March 17th 2025Global biosimilar regulatory harmonization will be needed to reduce development costs and improve patient access, despite challenges posed by differing national requirements and regulatory frameworks, according to review authors.
